These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17645549)

  • 1. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis.
    Decker M; Hofflich H; Elias AN
    Diabetes Obes Metab; 2008 Aug; 10(8):617-25. PubMed ID: 17645549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-cell function and anti-diabetic pharmacotherapy.
    Del Prato S; Bianchi C; Marchetti P
    Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.
    Lupi R; Del Prato S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S56-64. PubMed ID: 18640587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of thiazolidinediones in the management of type 2 diabetes: focus on ethnic minority populations.
    Umpierrez G; Dagogo-Jack S
    Ethn Dis; 2006; 16(1):51-7. PubMed ID: 16599348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor: a new player associated with apoptosis and proliferation of pancreatic beta-cell in type 1 diabetes mellitus.
    Li RJ; Qiu SD; Wang HX; Tian H; Wang LR; Huo YW
    Apoptosis; 2008 Aug; 13(8):959-71. PubMed ID: 18543106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPARĪ³-dependent and PPARĪ³-independent mechanisms.
    Rao JR; Keating DJ; Chen C; Parkington HC
    Diabetes Obes Metab; 2012 Nov; 14(11):983-9. PubMed ID: 22594400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crucial role of insulin receptor substrate-2 in compensatory beta-cell hyperplasia in response to high fat diet-induced insulin resistance.
    Takamoto I; Terauchi Y; Kubota N; Ohsugi M; Ueki K; Kadowaki T
    Diabetes Obes Metab; 2008 Nov; 10 Suppl 4():147-56. PubMed ID: 18834442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes.
    Leiter LA
    Diabet Med; 2005 Aug; 22(8):963-72. PubMed ID: 16026359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta cells in type 2 diabetes - a crucial contribution to pathogenesis.
    Maedler K
    Diabetes Obes Metab; 2008 May; 10(5):408-20. PubMed ID: 17451426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.
    Yang J; Zhang D; Li J; Zhang X; Fan F; Guan Y
    Clin Sci (Lond); 2009 Jan; 116(1):17-26. PubMed ID: 19037881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Closing the gap between clinical research and clinical practice: can outcome studies with thiazolidinediones improve our understanding of type 2 diabetes?
    Goldstein BJ
    Int J Clin Pract; 2006 Jul; 60(7):873-83. PubMed ID: 16846404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth.
    Holloway AC; Petrik JJ; Bruin JE; Gerstein HC
    Diabetes Obes Metab; 2008 Sep; 10(9):763-71. PubMed ID: 17970760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention.
    Karaca M; Magnan C; Kargar C
    Diabetes Metab; 2009 Apr; 35(2):77-84. PubMed ID: 19251449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
    Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
    Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.